Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hyperion Drops Drug After Fraud

by Ann M. Thayer
September 15, 2014 | A version of this story appeared in Volume 92, Issue 37

Hyperion Therapeutics has stopped development of DiaPep277, a diabetes drug it acquired in June with the purchase of Israel’s Andromeda Biotech. It did so after learning that some Andromeda employees colluded with an outside biostatistics firm to manipulate Phase III clinical trial data. The firm has suspended the employees involved and notified regulatory authorities. Hyperion expects to take a charge against earnings of up to $55 million. Andromeda had acquired much of its intellectual property from Germany’s Evotec. Evotec, which will take its own $11 million charge, claims that Hyperion owes it $4.4 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.